Safety Study of Plasma Treatment System to Treat Back Acne
Primary Purpose
Acne Vulgaris
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
MOE Antimicrobial Plasma Treatment System
Sponsored by
About this trial
This is an interventional treatment trial for Acne Vulgaris
Eligibility Criteria
Inclusion Criteria:
- Males and non-pregnant, non-nursing females age 18-40 years old.
- Presence of clinically-evident back acne.
- Minimum of 20 non-inflammatory lesions (open and closed comedones)
- Minimum of 30 total lesions (sum of inflammatory and non-inflammatory)
- Subject must have measurable sebum production.
- Subjects must be in generally good health.
- Must be able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
- Any nodulo-cystic lesions at Baseline
- Pregnancy or breast feeding
- Use of acne devices or systemic therapy with antibiotics within four months prior to start and throughout the duration of the study
- Intake of any oral retinoids within four months prior to study start and throughout the duration of the study
- Topical use of topical retinoids within two weeks prior to study start and throughout the duration of the study
- Topical use of antibiotics, steroids and/or other non-retinoid topical acne products within two weeks prior to study start and throughout the duration of the study
- Use of an experimental drug or device within 30 days prior to study start;
- Intake of hormonal therapy within 3 months prior to study start
- Use of topical products on the back containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
- Concomitant use of mega-doses of certain vitamins, such as vitamin D (>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
- Procedures on the skin of the back such as chemical or laser peel, microdermabrasion, photodynamic therapy) within the past 2 weeks or during the study.
- History or evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication
- Any significant medical conditions that could confound the interpretation of the study results.
- History of/or current skin cancer cancer
- Use of tanning booths, sun lamps within the past 2 weeks or during the study
- Any metallic implants or prostheses in the vicinity of the treatment site (such as shoulders, back, spine, pacemakers, etc.).
- Any known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.
- History of significant post-inflammatory hyperpigmentation at the sites of acne lesions.
- History of or is currently immunocompromised.
Sites / Locations
- Clinical Unit for Research Trials and Outcomes in Skin (CURTIS)
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Plasma
Arm Description
Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
Outcomes
Primary Outcome Measures
Change in number of reported adverse events
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01662349
Brief Title
Safety Study of Plasma Treatment System to Treat Back Acne
Official Title
A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Back Acne
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Terminated
Why Stopped
The study was stopped due to other research priorities.
Study Start Date
August 2012 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Moe Medical Devices
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety of treating human skin with atmospheric plasma and get an initial evaluation of the efficacy of this treatment for acne.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Plasma
Arm Type
Experimental
Arm Description
Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
Intervention Type
Device
Intervention Name(s)
MOE Antimicrobial Plasma Treatment System
Intervention Description
Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
Primary Outcome Measure Information:
Title
Change in number of reported adverse events
Time Frame
Change from Baseline to 1 month post-treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and non-pregnant, non-nursing females age 18-40 years old.
Presence of clinically-evident back acne.
Minimum of 20 non-inflammatory lesions (open and closed comedones)
Minimum of 30 total lesions (sum of inflammatory and non-inflammatory)
Subject must have measurable sebum production.
Subjects must be in generally good health.
Must be able and willing to comply with the requirements of the protocol.
Exclusion Criteria:
Any nodulo-cystic lesions at Baseline
Pregnancy or breast feeding
Use of acne devices or systemic therapy with antibiotics within four months prior to start and throughout the duration of the study
Intake of any oral retinoids within four months prior to study start and throughout the duration of the study
Topical use of topical retinoids within two weeks prior to study start and throughout the duration of the study
Topical use of antibiotics, steroids and/or other non-retinoid topical acne products within two weeks prior to study start and throughout the duration of the study
Use of an experimental drug or device within 30 days prior to study start;
Intake of hormonal therapy within 3 months prior to study start
Use of topical products on the back containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
Concomitant use of mega-doses of certain vitamins, such as vitamin D (>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
Procedures on the skin of the back such as chemical or laser peel, microdermabrasion, photodynamic therapy) within the past 2 weeks or during the study.
History or evidence of other skin conditions or diseases that may require concurrent therapy or may interfere with the evaluation of the study medication
Any significant medical conditions that could confound the interpretation of the study results.
History of/or current skin cancer cancer
Use of tanning booths, sun lamps within the past 2 weeks or during the study
Any metallic implants or prostheses in the vicinity of the treatment site (such as shoulders, back, spine, pacemakers, etc.).
Any known photosensitivity disorders felt by the investigators to preclude safe inclusion in the study.
History of significant post-inflammatory hyperpigmentation at the sites of acne lesions.
History of or is currently immunocompromised.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexandra B. Kimball, MD
Organizational Affiliation
Partners Healthcare System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Unit for Research Trials and Outcomes in Skin (CURTIS)
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Safety Study of Plasma Treatment System to Treat Back Acne
We'll reach out to this number within 24 hrs